MIFH
YMAB

Migdal Insurance & Financial Holdings’s Y-mAbs Therapeutics YMAB Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-730
Closed -$12K – 708
2021
Q4 		$12K Sell
730
-990
-58% -$21.2K ﹤0.01% 585
2021
Q3 		$49K Buy
+1,720
New +$54.2K ﹤0.01% 452

Other funds holding YMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

Migdal Insurance & Financial Holdings's YMAB Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Y-mAbs Therapeutics (YMAB) in Q1 2022, closing a stake of 730 shares — an estimated $12K sold.

Migdal Insurance & Financial Holdings first reported a position in YMAB in Q3 2021 and held it in 2 quarters. The position peaked at $49K in Q3 2021. 88 funds tracked by Wall St. Rank hold YMAB as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Y-mAbs Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 730 Y-mAbs Therapeutics shares in Q1 2022, an estimated $12K.
  • Migdal Insurance & Financial Holdings first reported a position in Y-mAbs Therapeutics in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Y-mAbs Therapeutics position peaked at $49K in Q3 2021.
  • 88 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.